Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?

Abstract

Next-generation sequencing (NGS) technologies and data have revolutionized cancer research and are increasingly being deployed to guide clinicians in treatment decision-making. NGS technologies have allowed us to take an “omics” approach to cancer in order to reveal genomic, transcriptomic, and epigenomic landscapes of individual malignancies. Integrative multi-platform analyses are increasingly used in large-scale projects that aim to fully characterize individual tumours as well as general cancer types and subtypes. In this review, we examine how NGS technologies in particular have contributed to “omics” approaches in cancer research, allowing for large-scale integrative analyses that consider hundreds of tumour samples. These types of studies have provided us with an unprecedented wealth of information, providing the background knowledge needed to make small-scale (including “N of 1”) studies informative and relevant. We also take a look at emerging opportunities provided by NGS and state-of-the-art third-generation sequencing technologies, particularly in the context of translational research. Cancer research and care are currently poised to experience significant progress catalyzed by accessible sequencing technologies that will benefit both clinical- and research-based efforts.

Genome variation across cancers scales with tissue stiffness – An invasion-mutation mechanism and implications for immune cell infiltration

“…This variability makes it necessary to isolate and sequence every individual tumor to identify its unique neo-antigen profile, which remains a resource-intensive challenge for current sequencing [66]. If the technology continues to advance, it is exciting to consider that personalized neo-antigen-based therapy could enter clinical practice [67,68]. …”

Whole-exome sequencing to identify somatic mutations in peritoneal metastatic gastric adenocarcinoma: A preliminary study

“…Whole-genome sequencing provides a relatively unbiased review of the genome but is costly and produces large datasets, which present a heavy computational burden. Thus, many researchers and clinicians choose whole-exome sequencing (WES) for personal management [15]. WES directly sequences all exonic regions, which account for only 1% of the whole genome, to accurately depict the relationship between mutations and phenotypes.…”

Next-generation sequencing in thyroid cancer

“…Previously, single gene assays were commonly used for finding molecular alterations in tumors. Presently, NGS technology provides the simultaneous analysis of hundreds of genes of interest, using targeted sequencing panels [1]. Thus, NGS-based molecular tests for oncology research and clinical practice appear to be rapidly evolving.…”